Evidence map›Paper›PMID 34503443›Full record

ArticleThe journal of headache and pain2021

Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey.

M Koch, Z Katsarava, C Baufeld, K Schuh, A Gendolla, A Straube, W von Pannwitz, W E Hofmann, S Ortler

Open access · goldAbstract read
In one paragraph

Article in The journal of headache and pain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

M KochNovartis Pharma GmbH, Roonstr. 25, 90429, Nuremberg, Germany.
Z KatsaravaChristian Hospital Unna, Unna, Germany.
C BaufeldNovartis Pharma GmbH, Roonstr. 25, 90429, Nuremberg, Germany.
K SchuhNovartis Pharma GmbH, Roonstr. 25, 90429, Nuremberg, Germany.
A Gendolla, Essen, Germany.
A StraubeDepartment of Neurology, Ludwig-Maximilians University, Munich, Germany.
W von Pannwitz, Berlin, Germany.
W E Hofmann, Aschaffenburg, Germany.
S OrtlerNovartis Pharma GmbH, Roonstr. 25, 90429, Nuremberg, Germany. sonja.ortler@novartis.com.
Novartis (Germany) · DEAschaffenburg University of Applied Sciences · DELudwig-Maximilians-Universität München · DEUniversity of Duisburg-Essen · DE

Funding

Novartis Pharma Novartis Pharma
6 · The paper itself

Abstract

backgroundMigraine is a primary headache disorder characterized by recurrent attacks that may have a significant impact on patients' daily life. Treatment options must often be re-evaluated in light of efficacy, tolerability and compliance issues. Few data on commonly applied treatment algorithms and treatment failures have existed in Germany in 2017/2018. The PANORAMA survey was designed to explore and characterize the migraine healthcare landscape and to demonstrate the medical treatment need at that time in Germany.

methodsThree different questionnaires were used to assess the profile of the 119 participating centers, characterize migraine patients at centers and evaluate qualitative aspects of the current migraine healthcare situation from a physician´s professional perspective. Data were analyzed as observed and summarized by descriptive statistics.

resultsThe results demonstrate that once referred to a migraine specialist, the majority of patients continue to be treated at a specialist. At specialized centers, 41.6 % of migraine patients receive prophylactic treatment. 45.4 % of prophylactic treatments are initiated with a beta-blocker and 28.1 % with an anti-epileptic. Pivotal factors to initiate prophylactic treatment are migraine attack frequency and intensity (58.0 %). Treatment decisions are largely based on prior / concomitant diseases and physical constitution of the patient (52.1 %). Following an inadequate treatment, most patients either switch substance class or discontinue prophylactic treatment.

conclusionsPANORAMA gives a comprehensive overview of the migraine healthcare landscape in Germany in 2017/2018, elucidates a lack of common treatment algorithms and reveals a high demand for defined therapy strategies and new prophylactic treatment going forwards.

Indexed as

Migraine DisordersAdrenergic beta-AntagonistsAnticonvulsantsGermanyHumansSurveys and QuestionnairesTreatment FailureAdrenergic beta-AntagonistsAnticonvulsantsHeadacheHealthcare systemsMigrainePatient carePreventive treatment

Identifiers

PMID34503443
PMCPMC8428142
OpenAlexW3196659674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.